China Growth Capital has led a US$20 million series A+ round in ABM Therapeutics, a Chinese clinical-stage biopharmaceutical company developing a new generation of BRAF inhibitor. Sinopharm Capital, Panlin Capital, Ming Bioventures and existing investors Kaitai Capital, LongDAC also participated. Proceeds will be used to accelerate the clinical development of ABM-1310 and multiple existing preclinical […] China Growth Capital Leads $20M Series A+ Round In ABM Therapeutics comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.